IMS 2024 | Interim results of a Phase II trial evaluating ISA-LEN for HR-SMM
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, outlines the evolution of smoldering myeloma (SMM) diagnosis and treatment and then shares the interim results of a Phase II trial evaluating isatuximab (ISA) and lenalidomide (LEN) in patients with high-risk (HR) smoldering myeloma. This study demonstrated a 90% overall response rate (ORR) at 18 months, setting the stage for the larger ongoing Phase III ITHACA trial (NCT04270409). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
